9 completed, 8 recruiting, 2 active not recruiting, 1 enrolling by invitation. 5 Phase 2, 4 Not applicable, 1 Early Phase 1, 1 Phase 1, 1 Phase 3.
Follow Cushing Disease: new trials by email Literature Review of Cushing Disease trials Research Report on Cushing Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease [18F]FET PET-MRI - Cushing Disease | Not applicable | Enrolling by invitation | University Hospital, Basel, Switzerland | 43 | 2026-06-04 | 2026-07-06 |
| FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET - Cushing Disease, Pituitary Adenoma | Early Phase 1 | Recruiting | Mayo Clinic | 50 | 2026-04-27 | 2026-10-30 |
| Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease Fimepinostat - Cushing Disease | Phase 2 | Recruiting | University of California, Los Angeles | 20 | 2025-01-16 | 2026-07-17 |
| Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors Contrast enhanced pituitary magnetic resonance imaging (MRI), Contrast enhanced ultrasound, Non-Contrast Ultrasound - Pituitary Adenoma, Cushing Disease | Recruiting | Mayo Clinic | 110 | 2024-06-19 | 2026-01-13 | |
| Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors. Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers - Cushing Disease, ACTH-producing Pituitary Tumour | Recruiting | Hospices Civils de Lyon | 20 | 2023-11-23 | 2026-03-11 | |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| Hair Cortisol and Cushing's Disease Patient group, Remission control group, Bilateral surrenalectomy control group - Cushing Disease | Not applicable | Completed | University Hospital, Bordeaux | 51 | 2021-03-10 | 2023-07-18 |
| Postoperative Thrombosis Prevention in Patients With CD LMWH/Rivaroxaban, IPC - Cushing Disease, DVT | Not applicable | Active not recruiting | Huashan Hospital | 206 | 2020-12-01 | 2025-07-02 |
| Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms Blood test, 24-hour Urine test, Saliva swab - Cushing Disease | Active not recruiting | Centre Hospitalier Universitaire de Nīmes | 380 | 2019-07-01 | 2025-11-17 | |
| Long-Term Follow-Up of Survivors of Pediatric Cushing Disease Cushing Disease | Recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 240 | 2019-03-04 | 2026-10-29 | |
| Open-label Treatment in Cushing's Syndrome Levoketoconazole - Cushing Syndrome, Cushing Disease | Phase 3 | Completed | Cortendo AB | 51 | 2019-01-07 | 2025-06-19 |
| Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Seliciclib - Cushing Disease | Phase 2 | Completed | Cedars-Sinai Medical Center | 5 | 2018-11-02 | 2026-10-16 |
| Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders circadian gene expression evaluation - Cushing Syndrome, Adrenal Insufficiency | Not applicable | Recruiting | University of Roma La Sapienza | 44 | 2018-07-04 | 2026-10-20 |
| Collecting Information About Treatment Results for Patients With Cushing's Syndrome Cushing's QoL (Quality of Life Questionnaire), Nottingham Health Profile (NHP), Hospital Anxiety and Depression Scale (HADS) - Cushing's Disease, Cushing Syndrome | Recruiting | Memorial Sloan Kettering Cancer Center | 300 | 2017-11-28 | 2026-10-26 | |
| Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015 Cushing Disease | Withdrawn | University Hospital, Brest | 2017-10-01 | 2026-06-26 | ||
| Cushing´s Disease Epidemiology in Sweden Cushing Disease | Completed | Vastra Gotaland Region | 502 | 2013-09-01 | 2019-05-03 | |
| The Factors Associated With the Recurrence in Patients With Cushing Disease Cushing Disease | Completed | National Taiwan University Hospital | 42 | 2013-06-01 | 2014-09-08 | |
| Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Pasireotide 0.6 MG/ML - Cushing Disease | Phase 4 | Completed | University of Palermo | 24 | 2013-05-01 | 2017-10-27 |
| Safety and Efficacy of LCI699 in Cushing's Disease Patients LCI699 - Cushings Disease, Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 31 | 2011-03-23 | 2021-01-22 |
| Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease Pasireotide - Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 19 | 2004-08-13 | 2021-06-02 |
Showing 20 of 21. Sign in to see all of them.
Pituitary ACTH Hypersecretion (21) · Cushing Syndrome (4) · Pituitary Diseases (2) · Pituitary Neoplasms (2) · ACTH Syndrome, Ectopic (1) · ACTH-Secreting Pituitary Adenoma (1) · Acromegaly (1) · Addison Disease (1) · Adrenal Insufficiency (1) · Adrenocortical Hyperfunction (1) · Carcinogenesis (1) · Combined Pituitary Hormone Deficiency (1) · Congenital Abnormalities (1) · Gigantism (1) · Metabolic Syndrome (1)
Brain Diseases (21) · Central Nervous System Diseases (21) · Endocrine System Diseases (21) · Hyperpituitarism (21) · Hypothalamic Diseases (21) · Nervous System Diseases (21) · Pituitary Diseases (19) · Adrenal Gland Diseases (5) · Neoplasms (5) · Adrenocortical Hyperfunction (4) · Endocrine Gland Neoplasms (4) · Neoplasms by Site (4) · Adenoma (2) · Brain Neoplasms (2) · Central Nervous System Neoplasms (2)
pasireotide (2) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1) · 4-amino-4'-hydroxylaminodiphenylsulfone (1) · Biomarkers (1) · Hematologic Tests (1) · Osilodrostat (1) · Perceived Stress Scale (1) · Roscovitine (1) · Tissue Banks (1) · Urinalysis (1) · fimepinostat (1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Mayo Clinic (2) · Novartis Pharmaceuticals (2) · Cedars-Sinai Medical Center (1) · Centre Hospitalier Universitaire de Nīmes (1) · Cortendo AB (1) · Crinetics Pharmaceuticals Inc. (1) · Hospices Civils de Lyon (1) · Huashan Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · National Taiwan University Hospital (1) · University Hospital, Basel, Switzerland (1) · University Hospital, Bordeaux (1) · University Hospital, Brest (1) · University of California, Los Angeles (1)
United States (11) · France (6) · Italy (4) · Netherlands (2) · Bulgaria (1) · China (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Japan (1) · Poland (1) · Romania (1) · Spain (1) · Sweden (1)
Deborah P Merke, M.D. (2) · David de Brauwere (1) · Derek Johnson, MD (1) · Fredric Cohen, MD (1) · Gudmundur Johannsson, Professor (1) · Ian Mark, MD (1) · Ning-Ai Liu, MD, PhD (1) · Shlomo Melmed, MD (1) · Tien-Chun Chang, M.D., Ph.D. (1)
PMID 19170709, PMID 19344074, PMID 22154461, PMID 23943009, PMID 24412141, PMID 24423285, PMID 25258026, PMID 27496264, PMID 29395172, PMID 30234410, PMID 32232325, PMID 32714280, PMID 36149413, PMID 37144820, PMID 40544300, PMID 40813536, PMID 41052284, PMID 41349930, PMID 41540017
2004 (1)